Indian Pediatric Ulcerative Colitis drugs market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Pediatric Ulcerative Colitis is an inflammatory bowel disease, which is found in the lining of the large intestine (colon or bowel) and rectum becomes inflamed. The inflammation cause diarrhea or frequent emptying of the colon. The Indian pharmaceutical industry has been consistently growing with the public and private investments, making India as a potential market for the treatment of prevailing diseases like Pediatric Ulcerative Colitis. Additionally, healthcare expenditure is playing a critical role in fueling the pediatric ulcerative colitis therapeutics market in India. With the substantial healthcare expenditure and various insurance schemes including PMJAY and Ayushman Bharat-National Health Protection Mission, the healthcare sector is improving on various fronts in India. Various aspects in which the Indian healthcare sector is improving upon includes a number of healthcare services, advanced diagnostic centers, induction of advanced treatment process, international collaborations, and developing infrastructure for healthcare services that further provide a significant opportunity to the market growth.
Market Growth Drivers
The market for Pediatric Ulcerative Colitis treatment is growing in India due to factors such as the increasing prevalence of ulcerative colitis and Crohn’s disease, advances in medical technology, government support for Pediatric Ulcerative Colitis treatment research. Moreover, the increasing number of drugs in clinical trials and the growing popularity of prebiotic and probiotic foods are likely to spur market growth. However, high capital investments required for drug discovery, unsatisfactory effectiveness of treatment, and stringent drug regulatory policies are restraining the development of the Pediatric Ulcerative Colitis treatment market.